8-K: Gritstone Bio Receives Nasdaq Delisting Notice Due to Low Share Price

Gritstone Bio has been notified by Nasdaq that it no longer meets the minimum bid price requirement for continued listing, as its stock price has fallen below $1.00 for 30 consecutive days.

Summary

• Gritstone Bio received a notice from Nasdaq on June 25, 2024, stating that the company's stock price has fallen below $1.00 per share for 30 consecutive business days.
• This means Gritstone Bio no longer meets the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• The company has been granted an initial compliance period of 180 calendar days, until December 23, 2024, to regain compliance.
• To regain compliance, the stock price must close at or above $1.00 for at least 10 consecutive business days before December 23, 2024.
• If the company fails to regain compliance by this date, it may be eligible for an additional 180-day grace period by transferring its listing to the Nasdaq Capital Market.
• To qualify for the additional grace period, Gritstone Bio must meet all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price, and provide written notice of its intention to cure the deficiency, potentially through a reverse stock split.
• If the company cannot cure the deficiency or is not eligible for the additional period, Nasdaq will issue a delisting notice, which the company can appeal.
• Gritstone Bio is considering actions to regain compliance but has not made any decisions yet, and there is no guarantee they will be successful.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's ability to regain compliance, leading to a low sentiment score.

Positives

• Gritstone Bio has been granted an initial 180-day compliance period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day grace period if it transfers to the Nasdaq Capital Market and meets other listing requirements.

Negatives

• Gritstone Bio's stock price has fallen below $1.00 for 30 consecutive business days, triggering a delisting notice from Nasdaq.
• There is no guarantee that the company will be able to regain compliance with the minimum bid price requirement or other Nasdaq listing criteria.

Risks

• The company faces the risk of being delisted from the Nasdaq Global Select Market if it cannot regain compliance by December 23, 2024.
• There is uncertainty regarding the actions the company will take to regain compliance and whether those actions will be successful.
• The company's stock price may be negatively impacted by the delisting notice and the uncertainty surrounding its future listing status.

Future Outlook

The company is considering actions to regain compliance with Nasdaq listing requirements, but no decisions have been made, and there is no assurance of success.

Management Comments

• The company is considering actions that it may take in response to this Notice in order to regain compliance with the continued listing requirements, but no decisions about a response have been made at this time.

Industry Context

Delisting notices are not uncommon for companies experiencing financial difficulties or a decline in stock price, and this situation highlights the challenges faced by companies in maintaining their listing status on major exchanges.

Comparison to Industry Standards

• Many biotech companies, especially those in the early stages of development, face challenges in maintaining their stock price above the minimum bid price requirement.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced similar delisting risks in the past, highlighting the volatility and risk associated with the biotech sector.
• A reverse stock split is a common strategy used by companies in this situation to increase their stock price and regain compliance, but it does not always guarantee long-term success.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the delisting notice.
• Employees may face uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• Gritstone Bio will consider actions to regain compliance with Nasdaq listing requirements.
• The company must achieve a stock price of $1.00 or more for at least 10 consecutive business days before December 23, 2024, to avoid delisting.
• The company may apply to transfer its listing to the Nasdaq Capital Market for an additional compliance period.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, reverse stock split, GRTS